0.05Open0.51Pre Close1 Volume163 Open Interest330.00Strike Price5.00Turnover43.07%IV34.77%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier26DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.0058Delta0.0006Gamma4897.80Leverage Ratio-0.0086Theta0.0010Rho28.24Eff Leverage0.0107Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet